Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets

Amphistas CEO Nicola Thompson said, "This financing round, led by an outstanding investor syndicate, is a strong endorsement of our world class team and our novel approach. Amphista will now accelerate its oncology pipeline towards the clinic and extend our portfolio into indications largely inaccessible by traditional TPD approaches, such as diseases of the central nervous system (CNS). Amphista represents a strong fit with Gildes longstanding strategy of identifying Europes leading science and of engaging with experienced drug developers to build and support high growth (bio)pharma companies." Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. Led by a highly accomplished and passionate team of veteran biopharma experts, BioMotivs innovative model efficiently aligns resources and capital to select, fund, manage and advance a portfolio of drug development programs.